Haemophilus influenzae type b vaccine + Commercial Haemophilus influenzae type b vaccine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Haemophilus Influenzae Type b
Conditions
Haemophilus Influenzae Type b
Trial Timeline
Nov 1, 2008 → Feb 1, 2009
NCT ID
NCT00808392About Haemophilus influenzae type b vaccine + Commercial Haemophilus influenzae type b vaccine
Haemophilus influenzae type b vaccine + Commercial Haemophilus influenzae type b vaccine is a phase 3 stage product being developed by Novartis for Haemophilus Influenzae Type b. The current trial status is completed. This product is registered under clinical trial identifier NCT00808392. Target conditions include Haemophilus Influenzae Type b.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00808392 | Phase 3 | Completed |
Competing Products
10 competing products in Haemophilus Influenzae Type b
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Comparator: Modified Process Vaccine + Comparator: COMVAX™ | Merck | Phase 3 | 77 |
| Vaxelis + PedvaxHIB | Merck | Approved | 85 |
| Haemophilus influenzae type b (Hib) vaccine | Novartis | Phase 3 | 77 |
| Haemophilus influenzae type b (Hib) vaccine | Novartis | Phase 3 | 77 |
| Haemophilus influenza type b conjugate vaccine | Novartis | Approved | 85 |
| Hib-CRM197 + Hib-TT | Novartis | Phase 3 | 77 |
| Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine) | Novartis | Phase 3 | 77 |
| Haemophilus influenzae type b | Novartis | Phase 1 | 33 |
| Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib) | Novartis | Phase 3 | 77 |
| DTaP-IPV/Hib | Sanofi | Pre-clinical | 22 |